Subscribe

BrainAurora Medical Technology Limited (6681.HK)

HKD1.83 +0.08 (+4.57%)
CN HKSE Healthcare Biotechnology
Address Room 1301, Building 3
Shaoxing, CN
CEO Long Jun Cai
Website 66nao.com
IPO 2025-01-08
ISIN KYG1300R1083

Explore sections of this company profile

Description

BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evaluation and intervention of cognitive impairments to treat vascular diseases, neurodegenerative diseases, psychological disorders, and child development deficiencies. The company develops the Brain Function Information Management Platform software system, an evidence-based, medical-grade DTx product; Basic Cognitive Testing Software, an assessment of patients for basic cognitive capacity; Cognitive Ability Supplemental screening and assessment software, a solution designed to facilitate healthcare professionals assessment of patients; and Dyslexia Supplemental Screening and Assessment Software, a solution designed to facilitate the assessment of risk of developmental dyslexia in children. It also develops covid-19 induced cognitive impairment assessment and recovery training software; ADHD assessment and treatment software; quantitative cognitive assessment software for depression; depression treatment software; and cognitive impairment assessment software and cognitive impairment treatment software solutions. In addition, the company provides marketing services. BrainAurora Medical Technology Limited was founded in 2012 and is headquartered in Shaoxing, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD1.83 +0.08 (+4.57%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
26M
Beta
2.49
Float Shares
316.98M
Free Float %
23.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-1.01% -13.78% -27.41% -37.04% -51.64% -54.35% -56.95% -11.71% -11.71% -11.71% -11.71%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.83
Ratings Trend (MoM) 100% Bullish
Rating 2025-08 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Biotechnology: +1.6%
    +79.9% ★
  • ✗
    EPS growth Biotechnology: +29.7%
    -72.0%
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -152.7%
  • ✗
    EBIT margin Biotechnology: +0.0%
    -132.2%
  • ✗
    ROIC Biotechnology: -16.1%
    -224.7%
  • ✓
    Share dilution Biotechnology: -3.4%
    -7.2% ★
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -2.04×
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (2.28) × ERP
WACC = 85% × Ke + 15% × Kd (4.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 1.83
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
220.05M
est: 237.30M (-7.3%)
423.48M
423.48M – 423.48M
+78.5% YoY
621.23M
621.23M – 621.23M
+46.7% YoY
EBITDA
-276.68M
est: -237.30M (-16.6%)
-423.48M
-423.48M – -423.48M
-78.5% YoY
-621.23M
-621.23M – -621.23M
-46.7% YoY
EBIT
-290.95M
est: -237.30M (-22.6%)
-423.48M
-423.48M – -423.48M
-78.5% YoY
-621.23M
-621.23M – -621.23M
-46.7% YoY
Net Income
-314.86M
est: -102.08M (-208.4%)
-45.37M
-45.37M – -45.37M
+55.6% YoY
34.03M
34.03M – 34.03M
+175.0% YoY
SGA
175.58M
est: 415.03M (-57.7%)
740.65M
740.65M – 740.65M
+78.5% YoY
1.09B
1.09B – 1.09B
+46.7% YoY
EPS
-0.27
est: -0.09 (-211.0%)
-0.04
-0.04 – -0.04
+55.6% YoY
0.03
0.03 – 0.03
+175.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
Ownership data is not available for this company yet.

Executive team

Top executives
EBIT / Employee
-1.76M
Shares Outstanding
1.36B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Zheng Tan Chief Strategy Officer & Chairman 1M male
Junjie Wang Chief Financial Officer & Joint Company Secretary — male
Longjun Cai Chief Executive Officer — male
Ying Man Sham Joint Company Secretary — female
Zhiyuan Lai Vice President of Market & Operation — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology